We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company product TLANDO is an oral testosterone replacement therapy TRT. It also has other produ... Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company product TLANDO is an oral testosterone replacement therapy TRT. It also has other products in the pipeline such as LPCN 1144 LPCN 1148 and LPCN 1107. Show more
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 PR Newswire SALT LAKE CITY, May 1, 2024 Pivotal study design aligned with FDA on streamlined...
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity PR Newswire SALT LAKE CITY, April 11, 2024 LPCN 2401 treatment resulted in...
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis PR Newswire SALT LAKE CITY, March 28, 2024 Met primary and HepaticΒ Encephalopathy (HE...
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 PR Newswire SALT LAKE CITY, March 25, 2024 Company anticipates topline results from this crossover pivotal study late in the...
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 PR Newswire SALT LAKE CITY, March 7, 2024 SALT LAKE CITY, March 7, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ:...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.28 | 6.33484162896 | 4.42 | 5.1 | 4.38 | 18835 | 4.6935217 | CS |
4 | -0.17 | -3.49075975359 | 4.87 | 7.15 | 4.38 | 150722 | 6.08956658 | CS |
12 | 0.77 | 19.5928753181 | 3.93 | 7.15 | 3.2 | 67077 | 5.70604819 | CS |
26 | 2.01 | 74.7211895911 | 2.69 | 7.15 | 2.35 | 45823 | 4.96403193 | CS |
52 | -0.06 | -1.26050420168 | 4.76 | 7.15 | 2.3101 | 88080 | 4.83929566 | CS |
156 | -19.44 | -80.5302402651 | 24.14 | 32.13 | 2.3101 | 372029 | 18.26512087 | CS |
260 | -26.75 | -85.0556438792 | 31.45 | 59.5 | 2.3101 | 975500 | 23.43142481 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions